Aardvark Therapeutics Inc. Common Stock (AARD)

FairStock Score: 32/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Aardvark Therapeutics as a Graham-style analyst, asking first whether there is a durable business with earnings and a margin of safety. Today, the answer is no. Aardvark is a clinical-stage biopharmaceutical company with 28 employees, focused on small-molecule therapeutics for metabolic diseases. In the filed figures, revenue is N/A in every period shown. It lost $20.6 million in FY2024 and $57.6 million in FY2025, so the annual loss widened. In fiscal Q1 2026, the quarter ended 2026-03-31, net loss was $21.6 million and diluted EPS was -$0.99. In fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $14.4 million and diluted EPS was -$0.66. The trailing free cash flow is -$69.4 million, and FairStock's FCF yield is -78.5% against an $88.4 million market cap. That is heavy cash consumption relative to the equity value. The balance sheet has low leverage—D/E 0.01—and FairStock's Altman Z-Score of 6.45 suggests low measured bankruptcy risk, but a Piotroski F-Score of 1/9 confirms weak fundamentals. Valuation is awkward: FairStock's P/E is -1.25, P/B is 1.18, and the stock at $4.04 on 2026-10-13 sits near the low end of its $3.35–$16.60 52-week range. A low price is not the same as a bargain. Without revenue, profits, or a commercial moat, the case rests on clinical trial outcomes and future financing. FairStock's Lynch category is none because only two years of filed results are available, not three. I would want a much larger margin of safety and evidence of pipeline progress before treating this as anything but speculative.

In plain English: Aardvark Therapeutics is a small healthcare company trying to develop new medicines for metabolic diseases. It has no product revenue yet and is losing money: it lost $57.6 million in fiscal 2025 and kept losing money in the first half of fiscal 2026. At $4.04 a share, the stock is near the low end of its 52-week range, but because the company has no sales or profits, the price is best seen as speculative rather than clearly cheap or expensive.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer